Early-stage primary bone lymphoma: A retrospective, multicenter Rare Cancer Network (RCN) study

Ling Cai, Michael C. Stauder, Yu Jing Zhang, Philip Poortmans, Ye Xiong Li, Nicolaos Constantinou, Juliette Thariat, Sidney P. Kadish, Tan Dat Nguyen, Youlia M. Kirova, Pirus Ghadjar, Damien C. Weber, Victoria Tuset Bertran, Mahmut Ozsahin, René Olivier Mirimanoff

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Purpose: Primary bone lymphoma (PBL) represents less than 1% of all malignant lymphomas. In this study, we assessed the disease profile, outcome, and prognostic factors in patients with Stages I and II PBL. Patients and Methods: Thirteen Rare Cancer Network (RCN) institutions enrolled 116 consecutive patients with PBL treated between 1987 and 2008 in this study. Eighty-seven patients underwent chemoradiotherapy (CXRT) without (78) or with (9) surgery, 15 radiotherapy (RT) without (13) or with (2) surgery, and 14 chemotherapy (CXT) without (9) or with (5) surgery. Median RT dose was 40 Gy (range, 4-60). The median number of CXT cycles was six (range, 2-8). Median follow-up was 41 months (range, 6-242). Results: The overall response rate at the end of treatment was 91% (complete response [CR] 74%, partial response [PR] 17%). Local recurrence or progression was observed in 12 (10%) patients and systemic recurrence in 17 (15%). The 5-year overall survival (OS), lymphoma-specific survival (LSS), and local control (LC) were 76%, 78%, and 92%, respectively. In univariate analyses (log-rank test), favorable prognostic factors for OS and LSS were International Prognostic Index (IPI) score ≤1 (p = 0.009), high-grade histology (p = 0.04), CXRT (p = 0.05), CXT (p = 0.0004), CR (p < 0.0001), and RT dose >40 Gy (p = 0.005). For LC, only CR and Stage I were favorable factors. In multivariate analysis, IPI score, RT dose, CR, and CXT were independently influencing the outcome (OS and LSS). CR was the only predicting factor for LC. Conclusion: This large multicenter retrospective study confirms the good prognosis of early-stage PBL treated with combined CXRT. An adequate dose of RT and complete CXT regime were associated with better outcome.

Original languageEnglish (US)
Pages (from-to)284-291
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume83
Issue number1
DOIs
StatePublished - May 1 2012
Externally publishedYes

Keywords

  • Combined treatment modality
  • Early stage
  • Primary bone lymphoma
  • Radiotherapy

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Early-stage primary bone lymphoma: A retrospective, multicenter Rare Cancer Network (RCN) study'. Together they form a unique fingerprint.

Cite this